<DOC>
	<DOCNO>NCT02101307</DOCNO>
	<brief_summary>This non-interventional study observe usage efficacy RoActemra/Actemra patient rheumatoid arthritis ( RA ) recently begin treatment . The treatment regimen direct treat physician accord clinical practice . Patients expect observed approximately 6 month begin treatment .</brief_summary>
	<brief_title>Multicenter , Post-marketing , Non-interventional , Observational Study RA Patients Treated With RoActemra/Actemra ( Tocilizumab )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Patients least 18 year age Patients diagnosis moderate severe RA accord revise ( 1987 ) ACR criterion Patient treat physician make decision commence RoActemra/Actemra treatment ( accordance local label ) . This include patient receive RoActemra/Actemra treatment within 8 week prior enrolment visit Patient give informed consent Patients receive RoActemra/Actemra 8 week prior enrolment visit Patients previously receive RoActemra/Actemra clinical trial compassionate use Patients receive treatment investigational agent within 4 week ( 5 halflives investigational agent , whichever long ) start treatment RoActemra/Actemra Patients history autoimmune disease joint inflammatory disease RA</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>